158 related articles for article (PubMed ID: 32965666)
1. The Prospective Incorporation of Molecular Profiling Will Transform Global Cancer Care.
Marshall JL
Oncology (Williston Park); 2020 Sep; 34(9):356-357. PubMed ID: 32965666
[No Abstract] [Full Text] [Related]
2. New developments on targeted cancer therapy: Multi-faceted issues in targeted cancer therapy.
Bao J; Qiao L
Cancer Lett; 2017 Feb; 387():1-2. PubMed ID: 28038727
[No Abstract] [Full Text] [Related]
3. Preface on application of omics technologies in cancer biology and therapy.
Georgakilas AG
Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153
[No Abstract] [Full Text] [Related]
4. Personalized cancer genomics: the road map to clinical implementation.
Yousef GM
Clin Chem; 2012 Apr; 58(4):661-3. PubMed ID: 22322979
[No Abstract] [Full Text] [Related]
5. Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers.
Ow TJ; Sandulache VC; Skinner HD; Myers JN
Cancer; 2013 Nov; 119(22):3914-28. PubMed ID: 24037788
[TBL] [Abstract][Full Text] [Related]
6. New ESMO scale ranks mutations as cancer medicine targets.
Fricker J
Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
[No Abstract] [Full Text] [Related]
7. [Improvement in pathological diagnosis for targeted therapy towards standardization].
Zheng J
Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):1-3. PubMed ID: 23611264
[No Abstract] [Full Text] [Related]
8. Molecular profiling for personalized cancer care.
Ashfaq R
Clin Exp Metastasis; 2012 Oct; 29(7):653-5. PubMed ID: 22678423
[TBL] [Abstract][Full Text] [Related]
9. Using single-cell transcriptomics to predict which tumors will respond to targeted therapy.
Nat Cancer; 2024 Jun; 5(6):825-826. PubMed ID: 38684925
[No Abstract] [Full Text] [Related]
10. Oncoproteomics: Trials and tribulations.
Zhou L; Li Q; Wang J; Huang C; Nice EC
Proteomics Clin Appl; 2016 Apr; 10(4):516-31. PubMed ID: 26518147
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathology in therapeutics: where are we now, and where are we going?
Harrison DJ; Faratian D
Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
[No Abstract] [Full Text] [Related]
13. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
14. Gene-expression profiling to predict responsiveness to immunotherapy.
Jamieson NB; Maker AV
Cancer Gene Ther; 2017 Mar; 24(3):134-140. PubMed ID: 27834354
[TBL] [Abstract][Full Text] [Related]
15. Rational design of cancer gene panels with OncoPaD.
Rubio-Perez C; Deu-Pons J; Tamborero D; Lopez-Bigas N; Gonzalez-Perez A
Genome Med; 2016 Oct; 8(1):98. PubMed ID: 27716338
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis reveals molecular patterns associated with age.
Shah Y; Verma A; Marderstein AR; White J; Bhinder B; Garcia Medina JS; Elemento O
Cell Rep; 2021 Dec; 37(10):110100. PubMed ID: 34879281
[TBL] [Abstract][Full Text] [Related]
18. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
19. Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation.
Hicks JK; McLeod HL
Biomark Med; 2019 Aug; 13(12):987-990. PubMed ID: 31385527
[No Abstract] [Full Text] [Related]
20. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
